• SteinCares strengthens its role as the regional partner for global pharmaceutical companies seeking to bring innovative therapies to Latin American patients.
• Through this agreement, the company will continue to expand access to innovative, high-quality, and cost-effective treatments for patients in Brazil.

São Paulo, Brazil – December 8th 2025 SteinCares, a leading specialty healthcare company in Latin America, today announced the addition of Monofer® (iron isomaltoside 1000) into its Brazilian portfolio, following the recent transfer of commercialization rights.

With this milestone, SteinCares strengthens its presence in Brazil and expands access to innovative treatments for iron deficiency anemia across multiple therapeutic areas, including hematology, oncology, cardiology, gastroenterology, gynecology, and nephrology.

Monofer® is an innovative intravenous iron replacement therapy indicated for the treatment of iron deficiency, with or without anemia, in patients across multiple therapeutic areas including hematology, oncology, cardiology, gastroenterology, gynecology, and nephrology. Unlike conventional IV iron therapies that require multiple administrations, Monofer® enables full iron repletion in a single infusion—helping reduce hospital visits, improve patient adherence, and optimize healthcare resources.

In Brazil, iron deficiency remains a clinical challenge, particularly among patients who are unable to tolerate or do not respond to oral iron supplementation. This is especially relevant in cases where rapid iron replenishment is needed, such as chronic kidney disease, chronic heart failure, inflammatory bowel disease, post-bariatric surgery, and significant blood loss.

The integration of Monofer® into SteinCares’ Brazilian operations reflects the company’s long-standing partnership with Pharmacosmos, the global innovator behind the therapy. This collaboration highlights SteinCares’ role as a trusted partner for international companies seeking to expand access to innovative therapies in Latin America, while ensuring that patients across the region benefit from consistent, high-quality management of iron deficiency.

“Bringing Monofer® under SteinCares’ umbrella in Brazil marks an important step in strengthening our portfolio, allowing us to consolidate the brand under our regional structure, ensuring alignment, continuity, and a unified vision for how Monofer® is managed across Latin America. At SteinCares, we are committed to being the bridge between global innovation and the unmet needs of patients and healthcare systems in our region,” said Julio Avella, Country Manager, SteinCares Brazil.

About SteinCares
SteinCares is a leader in the commercialization and distribution of specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars, plasma-derived treatments and complex generics. With 45 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global
pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.
For more information, please visit http://www.steincares.com/ or follow the company on LinkedIn.

About Pharmacosmos
PharmaCosmos is a leading company based in Denmark, with a track record of more than 50 years of innovation in iron and carbohydrate-based treatments and solutions for human and animal use. They have an R&D program focused on research and improving the quality of life of patients.
The company has affiliates in the Nordic countries, the United Kingdom and the United States, with products marketed in more than 80 countries around the world. Its manufacturing facilities are approved by regulatory authorities such as the Danish Medicines Agency and the U.S. FDA to ensure high quality products.
For more information, please visit https://pharmacosmos.com/